Compare Adaptive Biotechnologies Corp (ADPT) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Innodata Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.97 (market cap $4.04B), while Innodata Inc trades at $62.31 (market cap $2.05B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | INOD | |
|---|---|---|
Market Cap | $4.04B | $2.05B |
Sector | Health | Technology |
52-Week High | $25.45 | $121.50 |
52-Week Low | $12.30 | $34.45 |
Enterprise Value | $4.10B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
INOD trades at $61.40, down 1.33% today, but maintains a bullish technical signal with oscillators supporting upside momentum. The company reported strong Q2 2026 results, beating EPS estimates with $0.41 versus $0.21 expected, driven by 58% revenue growth and AI-driven demand expansion. Valuation ratios remain elevated with a P/E of 48.62, reflecting high growth expectations.
Outlook is positive given consistent earnings beats and AI sector tailwinds, but risks include premium valuation sensitivity and customer concentration. Analyst consensus is bullish with a $130 price target, suggesting significant upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
